STOCK TITAN
  1. Home
  2. Sec-filings
  3. VIR
  4. [144] Vir Biotechnology, Inc. SEC Filing

Vir Biotechnology (NASDAQ: VIR) ex-officer lines up more sales

Filing Impact
(Neutral)
Filing Sentiment
(Neutral)
Form Type
144

Rhea-AI Filing Summary

Vir Biotechnology, Inc. (VIR) is the issuer for a planned sale of common stock by Jason V. O'Byrne, identified as a former officer, under Rule 144. The notice covers up to 23,148 shares of common stock to be sold through Fidelity Brokerage Services LLC, with an aggregate market value of $242,591.04. Vir Biotechnology reports 169,215,958 shares of common stock outstanding as of 08/25/2026. In the prior three months, Jason V. O'Byrne sold 25,000 shares for $245,297.50 on 08/21/2026 and 14,352 shares for $142,123.55 on 08/24/2026. The planned sale is in connection with a stock option exercise, with sales expected on or about 08/25/2026 on NASDAQ.

Positive

  • None.

Negative

  • None.
Shares to be sold 23,148 shares Maximum Vir Biotechnology common shares covered by the Form 144 notice
Aggregate market value of securities to be sold $242,591.04 Value of the 23,148 shares covered by the Form 144
Shares outstanding 169,215,958 shares Vir Biotechnology common shares outstanding as of 08/25/2026
Recent sale 1 25,000 shares for $245,297.50 Sale of Vir Biotechnology common stock on 08/21/2026 by Jason V. O'Byrne
Recent sale 2 14,352 shares for $142,123.55 Sale of Vir Biotechnology common stock on 08/24/2026 by Jason V. O'Byrne
Approximate date of sale 08/25/2026 Planned sale date for shares covered by the Form 144 on NASDAQ
Rule 144 regulatory
"See the definition of "person" in paragraph (a) of Rule 144."
Rule 144 is a U.S. securities regulation that sets conditions under which restricted or insider-held shares can be legally resold to the public, such as required holding periods, availability of public information, limits on how much can be sold at once, and certain filing requirements. For investors it matters because it determines when previously locked-up shares can enter the market — like a release valve that can increase supply, affect share price, and signal insider intent.
Form 144 regulatory
"144: Filer Information"
Form 144 is a document that investors must file with the government when they plan to sell a large number of shares of a company's stock. It helps ensure transparency so everyone knows how many shares are being sold and when, which can impact the stock's price.
Stock Option Exercise financial
"Common | 08/25/2026 | Stock Option Exercise | Issuer"
A stock option exercise is the act of using a previously granted right to buy shares of a company's stock at a specific, predetermined price by paying that price and receiving the shares. It matters to investors because exercising changes who owns the shares (which can dilute existing ownership), can trigger taxable events and shift potential gains or losses, and affects voting power and the company’s outstanding share count—like turning a voucher into an actual product that becomes part of circulating supply.

FAQ

What does the Form 144 filing mean for Vir Biotechnology, Inc. (VIR)?
The filing reports that a former officer, Jason V. O'Byrne, may sell up to 23,148 shares of Vir Biotechnology common stock under Rule 144. This is a planned resale by an affiliate and does not represent new share issuance by the company.

How many VIR shares are covered by this Form 144 notice?
The notice covers up to 23,148 shares of Vir Biotechnology, Inc. common stock. The aggregate market value of these shares is listed as $242,591.04 in the filing.

How many Vir Biotechnology (VIR) shares are outstanding as reported in this filing?
Vir Biotechnology, Inc. reports 169,215,958 shares of common stock outstanding as of 08/25/2026. This figure is a baseline share count and is separate from the shares that may be sold under this Form 144.

What past sales by Jason V. O'Byrne in VIR stock are disclosed?
The filing discloses that Jason V. O'Byrne sold 25,000 shares for $245,297.50 on 08/21/2026 and 14,352 shares for $142,123.55 on 08/24/2026. These sales are in Vir Biotechnology common stock.

What is the relationship of the selling holder to Vir Biotechnology (VIR)?
The selling holder, Jason V. O'Byrne, is identified as a Former Officer of Vir Biotechnology, Inc. The Form 144 relates to sales for his account via Fidelity Brokerage Services LLC.

On which market are the VIR shares in this Form 144 expected to be sold?
The shares covered by this Form 144 are expected to be sold on NASDAQ, as specified in the filing, with an approximate sale date of 08/25/2026.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google

144: Filer Information

144: Issuer Information

144: Securities Information



Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold


* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.



Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

144: Remarks and Signature

Source: View Original Filing on SEC EDGAR